Long-Term Effect Of One Phase III Trial: Benefit For Thousands Of Patients
High Dose Radiotherapy Plus Chemo Encouraging For Small Cell Lung Cancer
Age Shouldn’t Determine Lung Cancer Treatment, ASCO Says In New Guideline
Patch-Lozenge Combination Best For Smoking Cessation
Lower Dose Dexamethasone Can Be Used To Treat Newly Diagnosed Myeloma
Low Total Cholesterol Linked To Higher Risk Of Cancer; Higher HDL Associated With Decreased Risk Of Cancer
Black-White Disparity Seen In End Of Life Treatment
HER2+ Tumors Increase Risk Of Recurrence, Study Finds
The Clinical Cancer Letter To End Print Edition In 2010
NCI Cooperative Group Clinical Trials Approved
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds
- A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. - Did peer review fail? Nature Medicine’s chronotherapy paper retraction raises questions
- A new diagnostic lens—and a lasting scientific legacy
- OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill
